4SC AG EV/Sales
What is the EV/Sales of 4SC AG?
The EV/Sales of 4SC AG is N/A
What is the definition of EV/Sales?
Enterprise value to sales ratio compares a company’s total value to its sales.
ttm (trailing twelve months)
Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.
EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.
EV/Sales of companies in the Health Care sector on XETRA compared to 4SC AG
What does 4SC AG do?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Companies with ev/sales similar to 4SC AG
- Xenetic Biosciences Inc has EV/Sales of N/A
- Third Point Offshore Investors has EV/Sales of N/A
- AIB plc has EV/Sales of N/A
- Primorus Investments plc has EV/Sales of N/A
- Arowana Australasian Value Opportunities Fund Ltd has EV/Sales of N/A
- ReNeuron plc has EV/Sales of N/A
- 4SC AG has EV/Sales of N/A
- Royal Bank of Scotland Plc has EV/Sales of N/A
- RiverNorth Flexible Municipal Income Fund Inc has EV/Sales of N/A
- Pulmatrix Inc has EV/Sales of N/A
- EML Payments has EV/Sales of N/A
- Independent Investment Trust Plc has EV/Sales of N/A
- Dividend 15 Split II has EV/Sales of N/A